[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2019002875A1 - Derivados de imidazol pentacíclico fusionado como modulares de la actividad de tnf. - Google Patents

Derivados de imidazol pentacíclico fusionado como modulares de la actividad de tnf.

Info

Publication number
CL2019002875A1
CL2019002875A1 CL2019002875A CL2019002875A CL2019002875A1 CL 2019002875 A1 CL2019002875 A1 CL 2019002875A1 CL 2019002875 A CL2019002875 A CL 2019002875A CL 2019002875 A CL2019002875 A CL 2019002875A CL 2019002875 A1 CL2019002875 A1 CL 2019002875A1
Authority
CL
Chile
Prior art keywords
disorders
modulars
imidazole derivatives
tnf activity
fused pentacyclic
Prior art date
Application number
CL2019002875A
Other languages
English (en)
Inventor
Helen Tracey Horsley
Haro Garcia Teresa De
Mengyang Xuan
Zhaoning Zhu
Daniel Christopher Brookings
Martin Clive Hutchings
James Andrew Johnson
Yann Foricher
Malcolm Maccoss
Original Assignee
Ucb Biopharma Sprl Belgica Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl Belgica Sanofi filed Critical Ucb Biopharma Sprl Belgica Sanofi
Publication of CL2019002875A1 publication Critical patent/CL2019002875A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN COMPUESTO DE FÓRMULA (1) COMO SE DEFINE EN LA MEMORIA DESCRIPTIVA, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, COMO MODULADORES POTENTES DE LA ACTIVIDAD DE TNFa HUMANO, LOS CUALES POR CONSIGUIENTE SON BENEFICIOSOS PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DE DIVERSAS ENFERMEDADES HUMANAS, INCLUYENDO TRASTORNOS AUTO INMUNOLÓGICOS E INFLAMATORIOS; TRASTORNOS NEUROLÓGICOS Y NEURODEGENERATIVOS; DOLOR Y TRASTORNOS NOCICEPTIVOS; TRASTORNOS CARDIOVASCULARES; TRASTORNOS METABÓLICOS; TRASTORNOS OCULARES; Y TRASTORNOS ONCOLÓGICOS.
CL2019002875A 2017-04-25 2019-10-09 Derivados de imidazol pentacíclico fusionado como modulares de la actividad de tnf. CL2019002875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25

Publications (1)

Publication Number Publication Date
CL2019002875A1 true CL2019002875A1 (es) 2020-03-06

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002875A CL2019002875A1 (es) 2017-04-25 2019-10-09 Derivados de imidazol pentacíclico fusionado como modulares de la actividad de tnf.

Country Status (33)

Country Link
US (3) US10980814B2 (es)
EP (2) EP3939980B1 (es)
JP (2) JP7083358B2 (es)
KR (1) KR102565132B1 (es)
CN (1) CN110582495B (es)
AR (1) AR111426A1 (es)
AU (1) AU2018259040B2 (es)
BR (1) BR112019020314A2 (es)
CA (1) CA3058980A1 (es)
CL (1) CL2019002875A1 (es)
CO (1) CO2019012856A2 (es)
CR (1) CR20190526A (es)
DK (1) DK3615534T3 (es)
EA (1) EA039049B1 (es)
ES (2) ES2956555T3 (es)
HR (1) HRP20211927T1 (es)
HU (1) HUE056593T2 (es)
IL (1) IL269890B (es)
LT (1) LT3615534T (es)
MA (2) MA49055B1 (es)
MX (1) MX2019012443A (es)
MY (1) MY197212A (es)
PE (1) PE20200662A1 (es)
PH (1) PH12019502182A1 (es)
PL (2) PL3615534T3 (es)
PT (2) PT3939980T (es)
RS (1) RS62596B1 (es)
SG (1) SG11201908871SA (es)
SI (1) SI3615534T1 (es)
TW (1) TWI801378B (es)
UY (1) UY37700A (es)
WO (1) WO2018197503A1 (es)
ZA (1) ZA201906255B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219609B (zh) * 2016-04-01 2022-02-01 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合六环咪唑衍生物
JP7429694B2 (ja) * 2018-10-24 2024-02-08 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレータとしての縮合五環式イミダゾール誘導体
WO2024223740A1 (en) 2023-04-26 2024-10-31 Sanofi Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428293B (zh) * 2012-06-11 2018-06-08 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
CN104619709B (zh) * 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI719949B (zh) * 2014-10-03 2021-03-01 比利時商Ｕｃｂ生物製藥公司 稠合五環咪唑衍生物
AR104291A1 (es) * 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf

Also Published As

Publication number Publication date
WO2018197503A1 (en) 2018-11-01
PL3939980T3 (pl) 2024-02-05
ZA201906255B (en) 2021-01-27
PL3615534T3 (pl) 2022-01-31
CA3058980A1 (en) 2018-11-01
EP3615534A1 (en) 2020-03-04
JP7299382B2 (ja) 2023-06-27
ES2956555T3 (es) 2023-12-22
MY197212A (en) 2023-06-01
SG11201908871SA (en) 2019-10-30
PH12019502182A1 (en) 2020-06-08
CN110582495B (zh) 2022-04-01
PT3939980T (pt) 2023-08-07
EA039049B1 (ru) 2021-11-26
PT3615534T (pt) 2021-10-21
MA57699B1 (fr) 2023-11-30
CR20190526A (es) 2020-01-07
SI3615534T1 (sl) 2022-01-31
US20210252012A1 (en) 2021-08-19
US20230250105A1 (en) 2023-08-10
UY37700A (es) 2018-11-30
NZ758198A (en) 2024-01-26
DK3615534T3 (da) 2021-10-18
MX2019012443A (es) 2020-01-13
RS62596B1 (sr) 2021-12-31
EA201992407A1 (ru) 2020-04-06
JP2022116233A (ja) 2022-08-09
US10980814B2 (en) 2021-04-20
AU2018259040B2 (en) 2022-04-28
EP3939980A1 (en) 2022-01-19
JP2020517637A (ja) 2020-06-18
US20200046723A1 (en) 2020-02-13
TW201841918A (zh) 2018-12-01
EP3939980B1 (en) 2023-07-26
ES2893807T3 (es) 2022-02-10
KR20190141200A (ko) 2019-12-23
MA49055A (fr) 2021-05-05
HUE056593T2 (hu) 2022-02-28
CO2019012856A2 (es) 2020-01-17
TWI801378B (zh) 2023-05-11
JP7083358B2 (ja) 2022-06-10
PE20200662A1 (es) 2020-06-11
MA49055B1 (fr) 2021-12-31
IL269890B (en) 2022-03-01
EP3615534B1 (en) 2021-09-15
AR111426A1 (es) 2019-07-10
AU2018259040A1 (en) 2019-10-31
KR102565132B1 (ko) 2023-08-08
BR112019020314A2 (pt) 2020-04-28
CN110582495A (zh) 2019-12-17
LT3615534T (lt) 2021-11-25
HRP20211927T1 (hr) 2022-03-18

Similar Documents

Publication Publication Date Title
ECSP17027306A (es) Derivados de imidazol pentacíclicos fusionados
CA2931589C (en) Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
CL2019002875A1 (es) Derivados de imidazol pentacíclico fusionado como modulares de la actividad de tnf.
EA201500130A1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
TR201908447T4 (tr) Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri.
TR201909614T4 (tr) Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri.
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.
PH12017500164A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112018069936A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
EA201792686A1 (ru) Производные индазола в качестве модуляторов активности tnf
CL2016001441A1 (es) Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes.
TR201910983T4 (tr) Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri.
BR112018069941A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
EA201892144A1 (ru) Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
EA201892149A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
CL2019001511A1 (es) Derivado de benzimidazol sustituido como modulador de la actividad del factor de necrosis tumoral.
NZ758198B2 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
ITUB20153076A1 (it) Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento.
MA40553A (fr) Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes